Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

被引：100

作者：

Fernandez de Larrea, Carlos ^{[1
]}

Kyle, Robert ^{[2
]}

Rosinol, Laura ^{[1
]}

Paiva, Bruno ^{[3
]}

Engelhardt, Monika ^{[4
]}

Usmani, Saad ^{[5
]}

Caers, Jo ^{[6
]}

Gonsalves, Wilson ^{[2
]}

Schjesvold, Fredrik ^{[7
]}

Merlini, Giampaolo ^{[8
]}

Lentzch, Suzanne ^{[9
]}

Ocio, Enrique ^{[10
]}

Garderet, Laurent ^{[11
]}

Moreau, Philippe ^{[12
]}

Sonneveld, Pieter ^{[13
]}

Badros, Ashraf ^{[14
]}

Gahrton, Gosta ^{[15
]}

Goldschmidt, Hartmut ^{[16
]}

Tuchman, Sascha ^{[17
]}

Einsele, Hermann ^{[18
]}

Durie, Brian ^{[19
]}

Wirk, Baldeep ^{[20
]}

Musto, Pellegrino ^{[21
]}

Hayden, Patrick ^{[22
]}

Kaiser, Martin ^{[23
]}

San Miguel, Jesus ^{[3
]}

Blade, Joan ^{[1
]}

Rajkumar, S. Vincent ^{[2
]}

Victoria Mateos, Maria ^{[10
]}

机构：

[1] Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Amyloidosis & Myeloma Unit, Dept Hematol, Barcelona, Spain

[2] Mayo Clin, Div Hematol, Internal Med, Rochester, MN USA

[3] Clin Univ Navarra, Ctr Invest Med Aplicada, Inst Invest Sanitaria Navarra, Pamplona, Spain

[4] Univ Med Ctr Freiburg, Med Dept, Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany

[5] Levine Canc Inst, Hemat Oncol & Blood Disorders, Charlotte, NC USA

[6] CHU Liege, Dept Hematol, Liege, Belgium

[7] Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway

[8] Univ Pavia, Dept Mol Med, Pavia, Italy

[9] Columbia Univ, Dept Med, New York, NY USA

[10] IBMCC USAL CSIC, Hosp Univ Salamanca IBSAL, Dept Hematol, Salamanca, Spain

[11] Hop St Antoine, Serv Hematol & Therapie Cellulaire, Paris, France

[12] Univ Hosp Nantes, Dept Hematol, Nantes, France

[13] Erasmus MC, Dept Hematol, Zuidholland, Netherlands

[14] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[15] Karolinska Inst, Dept Med, Stockholm, Sweden

[16] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[17] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[18] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[19] Cedars Sinai 2 Med Ctr, Samuel Oschin Comprehens Canc Inst, Hematol Oncol, Los Angeles, CA USA

[20] Penn State Canc Inst, Bone Marrow Transplant Program, Hershey, PA USA

[21] Referral Canc Ctr Basilicata, IRCCS CROB, Vulture, Italy

[22] St James Hosp, Dept Haematol, Dublin, Ireland

[23] Inst Canc Res, Myeloma Mol Therapy Grp, London, England

来源：

BLOOD CANCER JOURNAL | 2021年 / 11卷 / 12期

关键词：

SMOLDERING MULTIPLE-MYELOMA; FLOW-CYTOMETRY; HIGH-RISK; SURVIVAL; BORTEZOMIB; TRANSPLANTATION; QUANTIFICATION; DEXAMETHASONE; DISORDERS; CRITERIA;

D O I：

10.1038/s41408-021-00587-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of >= 5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.

引用

页数：5

共 34 条

[1] Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients
An, Gang
Qin, Xiaoqi
Acharya, Chirag
Xu, Yan
Deng, Shuhui
Shi, Lihui
Zang, Meirong
Sui, Weiwei
Yi, Shuhua
Li, Zengjun
Hao, Mu
Feng, Xiaoyan
Jin, Fengyan
Zou, Dehui
Qi, Junyuan
Zhao, Yaozhong
Tai, Yu-Tzu
Wang, Jianxing
Qiu, Lugui
[J]. ANNALS OF HEMATOLOGY, 2015, 94 (02) : 257 - 264
[2] Billadeau D, 1996, BLOOD, V88, P289
[3] Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia
Bladé, J
Kyle, RA
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (06) : 1259 - +
[4] Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
D'Arena, G.
Valentini, C. G.
Pietrantuono, G.
Guariglia, R.
Martorelli, M. C.
Mansueto, G.
Villani, O.
Onofrillo, D.
Falcone, A.
Specchia, G.
Semenzato, G.
Di Renzo, N.
Mastrullo, L.
Venditti, A.
Ferrara, F.
Palumbo, A.
Pagano, L.
Musto, P.
[J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1499 - 1502
[5] PRIMARY PLASMA-CELL LEUKEMIA
DIMOPOULOS, MA
PALUMBO, A
DELASALLE, KB
ALEXANIAN, R
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (04) : 754 - 759
[6] Primary plasma cell leukemia and autologous stem cell transplantation
Drake, Mary B.
Iacobelli, Simona
van Biezen, Anja
Morris, Curly
Apperley, Jane F.
Niederwieser, Dietger
Bjorkstrand, Bo
Gahrton, Gosta
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05): : 804 - 809
[7] Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Fernandez de Larrea, C.
Kyle, R. A.
Durie, B. G. M.
Ludwig, H.
Usmani, S.
Vesole, D. H.
Hajek, R.
San Miguel, J. F.
Sezer, O.
Sonneveld, P.
Kumar, S. K.
Mahindra, A.
Comenzo, R.
Palumbo, A.
Mazumber, A.
Anderson, K. C.
Richardson, P. G.
Badros, A. Z.
Caers, J.
Cavo, M.
Leleu, X.
Dimopoulos, M. A.
Chim, C. S.
Schots, R.
Noeul, A.
Fantl, D.
Mellqvist, U-H
Landgren, O.
Chanan-Khan, A.
Moreau, P.
Fonseca, R.
Merlini, G.
Lahuerta, J. J.
Blade, J.
Orlowski, R. Z.
Shah, J. J.
[J]. LEUKEMIA, 2013, 27 (04) : 780 - 791
[8] Primary plasma cell leukemia:: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics
García-Sanz, R
Orfao, A
González, M
Tabernero, MD
Bladé, J
Moro, MJ
Fernández-Calvo, J
Sanz, MA
Pérez-Simón, JA
Rasillo, A
San Miguel, JF
[J]. BLOOD, 1999, 93 (03) : 1032 - 1037
[9] Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study
Ge, Alex
Huang, Chiung-Yu
Martin, Thomas, III
Wolf, Jeffrey L.
Shah, Nina
Wong, Sandy W.
[J]. BLOOD, 2020, 136
[10] Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression
Gonsalves, W. I.
Rajkumar, S. V.
Dispenzieri, A.
Dingli, D.
Timm, M. M.
Morice, W. G.
Lacy, M. Q.
Buadi, F. K.
Go, R. S.
Leung, N.
Kapoor, P.
Hayman, S. R.
Lust, J. A.
Russell, S. J.
Zeldenrust, S. R.
Hwa, L.
Kourelis, T. V.
Kyle, R. A.
Gertz, M. A.
Kumar, S. K.
[J]. LEUKEMIA, 2017, 31 (01) : 130 - 135

← 1 2 3 4 →